To celebrate International Women’s Day 2023, we wanted to recognise the amazing women who work at Parkwalk and the women founders and innovators behind some of our portfolio companies. This year’s International Women’s Day theme is #EmbraceEquity; the aim being to get the world talking about ‘Why Equal Opportunities Aren’t Enough’. International Women’s Day highlights women’s
Wisdom joined the Investment team as an analyst in March 2023 and is working on statistical analysis, building VCRM and other relationships databases. Wisdom graduated in 2022, receiving a first class honours degree in Mathematics from Coventry University.
Zomp is a University of Cambridge spin-out which is building the world’s first 3D imaging cytometer and cell sorter. This new 3D imaging cytometry will revolutionise cell sorting and analysis, enabling the accurate measurement and sorting of single cells at high throughput based on observable characteristics.
As part of our annual Portfolio Showcase in 2022, we had the opportunity to sit down with some of our portfolio companies to speak to them about their experiences. We have showcased these in our ‘Meet the Portfolio’ series of videos below. Digital Health & MedTech Hear from the founders of animal health therapeutics specialists
We are thrilled to announce our latest investment into Quantum Motion Technologies as part of a £42m funding round, the largest funding round in UK quantum computing. The University of Oxford spin-out is developing a revolutionary technology platform using a scalable array of qubits creating quantum architecture compatible with standard silicon processing. This latest funding
Parkwalk is delighted to celebrate International Day of Women and Girls in Science 2023. This year we focus on the endless opportunities STEM opens for women and girls, around the globe. Parkwalk’s own Dr Cassie Doherty, Dr Karolina Zapadka and Claire Pardo share their thoughts on how STEM subjects have helped to shape their careers,
Signaloid has developed an innovative computing platform for tracking uncertainty in data while executing applications. The Company’s computing platform can achieve this at speeds significantly faster than existing solutions. Signaloid is focusing on a cloud-based deployment of its computing platform, allowing for seamless integration with existing cloud-based data processing workloads.
2022 was another eventful year, especially with the global economic, political and social situation. Despite the turbulence of 2022, Parkwalk has seen yet another successful and busy year. We want to take this time to wish a Happy New Year to all our investors, partners, supporters and portfolio management teams who have developed such impactful
We’re delighted to announce our recent investment in Qkine, as part of a £4.3m funding round. The University of Cambridge spin-out has designed a proprietary refolding technology and protein purification technique to produce high quality growth factors in E.coli. This latest funding round will help to grow manufacturing at scale, research and development and other
Parkwalk is thrilled to announce our win at the Growth Investor Awards 2022. Parkwalk was awarded ‘Best EIS Investment Manager’, recognising our deployment of capital, fundraising and returns to our investors. Now in their 8th year, the Growth Investor Awards were organised by Intelligent Partnership. It was a night to celebrate businesses and individuals within
We’re thrilled to announce our latest investment into Diffblue. The University of Oxford spin-out uses AI to write unit tests that help software teams and organisations efficiently improve their code coverage and quality. The funding round will help the company to automate its software writing platform whilst adding new code writing capabilities. Oxford, United Kingdom,
As the Autumn budget is right around the corner and the EIS sunset clause still set to be removed, our Investment Director Martin Glen, discusses a number of reasons why short-term politics should not impact longer term investment into research and development, in a recent article. Click here to read the full article. Thankfully, the
We’re delighted to announce the latest funding round for Cambridge GaN Devices, a University of Cambridge spin-out creating and developing the next generation of fabless semiconductors, using energy-efficient GaN-based power devices. This latest funding round will aim to deliver mass production of its GaN transistor family, whilst contributing to the global sustainability movement. Cambridge, UK
Amy joined Parkwalk as Legal Counsel in 2022. Prior to Parkwalk, she was an Emerging Companies associate at law firm Taylor Vinters where she advised start-up companies on a broad range of corporate and commercial matters alongside providing advice to companies and investors on investments. She gained her LLB in Law and American Law at
Barbara joined the Investor Relations team in November 2022 and assists with client onboarding, maintaining the investor database, and liaising with investors, advisers, and wealth managers. Barbara graduated from the University of Sussex, in 2022, with a BSc in Economics.
Parkwalk is delighted to announce an investment into Enhanc3D Genomics as part of a £10m Series A funding round. The Cambridge University spin-out has designed a platform that combines molecular biology technology with machine learning to discover the full potential of the human genome’s 3D organisation. The funding round will allow the company to rapidly
Enhanc3D Genomics is developing a proprietary technology that simultaneously profiles 3D genome folding at high resolution for all genes and their enhancers. This links gene enhancers and non-coding genetic variants to their target genes.
Sano Genetics is building a fully personalised software platform that acts as a “virtual Biobank” for genetic data, medical records and other ‘omics data’, enabling rapid and cost-effective recruitment of patients for clinical trials and precision medicine research.
Spirea is developing the next generation of Antibody-Drug Conjugate (ADC) drugs for cancer treatment. The company have designed a novel, wholly owned linker technology to improve ADC efficacy and tolerability. ADCs are drugs that combine both antibody and cytotoxic drugs via a linker molecule to target the tumour cell.
Crypto Quantique is an Internet of Things (IoT) security company with a mission to revolutionise the IoT with quantum driven cybersecurity. The company provides a dual hardware and software end-to-end solution to current and future cyber security threats to IoT security.
